Clinical Trials
Biosyngen’s EBV-Specific CAR-T Therapy, BRG01, Secures FDA Approval for Pivotal Phase II Trial in U.S.
Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with...
August 13, 2024 | News
Angiex Initiates Patient Dosing in Phase 1 Clinical Trial of AGX101, a First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for Solid Cancers
Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for t...
August 12, 2024 | News
Pulnovo Medical Launches Asia's First International Clinical Study on PADN at Singapore's National Heart Centre
Pulnovo Medical Limited,a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to announce...
August 10, 2024 | News
NEC Bio Therapeutics and AGC Biologics Partner to Enhance Production of Personalized Cancer Vaccine
NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria-based D...
August 08, 2024 | News
Senhwa Biosciences Receives FDA Green Light for Phase I/II Trial of Silmitasertib in Pediatric Relapsed Refractory Solid Tumors
Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious disea...
August 07, 2024 | News
Oxford Nanopore Partners with Singapore's NPM to Map Genomic Diversity of Major Ethnic Groups
Oxford Nanopore Technologies (Oxford Nanopore) has announced a landmark project with Singapore's National Precision Medicine (NPM) programme, led by Precis...
August 05, 2024 | News
Bayer Submits New Drug Application to FDA for Elinzanetant, a Novel Non-Hormonal Treatment for Menopausal Hot Flashes
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency...
August 02, 2024 | News
Bridge Biotherapeutics Completes Patient Enrollment for Phase 2 Study of BBT-877 in IPF Treatment
Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, an...
July 30, 2024 | News
Menarini Group Announces Positive Phase 3 Trial Results for Obicetrapib in Lowering LDL-C
-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically ...
July 30, 2024 | News
Daewoong Pharmaceutical's Bersiporocin Shows Positive Safety Data in Phase 2 Trial for IPF
Daewoong Pharmaceutical (Co-CEOs Chang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN...
July 30, 2024 | News
Eluminex Biosciences Administers First Dose of EB-105 to Diabetic Macular Edema Patient in US
Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient in...
July 29, 2024 | News
ObvioHealth Secures Strategic Investment from Guardant Health to Boost Oncology Clinical Trials
ObvioHealth, a global digital clinical trials company, announces a new strategic investment by Guardant Health, Inc., a leading precision oncology company ...
July 26, 2024 | News
Sirnaomics Completes IND-Enabling Studies for siRNA Therapeutic STP125G Targeting ApoC3
Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”),...
July 24, 2024 | News
Pfizer Opens SGD$1 Billion Green Mark Gold-Certified API Manufacturing Facility in Singapore
Invests SGD$1 billion to produce small molecule APIs for oncology, pain, and antibiotic medicines The facility is Green Mark ‘Go...
July 23, 2024 | News
Most Read
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
